Research Article Details
| Article ID: | A26495 |
| PMID: | 20394204 |
| Source: | Vnitr Lek |
| Title: | [Prevalence of liver disease markers among patients with metabolic risk factors]. |
| Abstract: | INTRODUCTION: Non-alcoholic fatty liver disease is one of the most common liver diseases. It's prevalence among patients with metabolic risk factors (obesity, type 2 diabetes, hypertension, lipid disorders) without previously recognized liver disease is not completely known. Aims of our study were to determine the prevalence of liver lesions (elevated alanin aminotransferase (ALT), gamma glutamyl transpeptidase (GGT) above normal range and ultrasound signs of liver steatosis) among the study group of patients with at least one metabolic risk factor, to compare it with the control group with no risk factor, to investigate it's association with the number of metabolic risk factors and to identify it's closest independent predictors. METHODS: Patients with other known liver diseases were excluded. Among 482 patients 429 were in the study group and 53 in the control group. RESULTS: In the study group the prevalence ofALT, GGT elevation and signs ofsteatosis was 12.1, 29.9, 38.3%, comparing to 5.7, 11.9 and 5.7% in the control group respectively. The differences were statistically significant. With the increasing number of risk factors we found growing prevalence of GGT elevation and signs of steatosis, but ALT elevation was equally prevalent. In multiple logistic regression the only independent predictor of ALT elevation was obesity, predictors of GGT elevation were type 2. diabetes and signs of steatosis, signs of steatosis were independently associated with overweight, obesity, type 2 diabetes and hypertriglyceridemia. CONCLUSIONS: Markers of liver disease do have a clinical and prognostic impact on the liver and cardiometabolic risk and therefore we suggest they should be actively screened in this group of patients. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|